The recent trials for aspirin in the prevention of cardiovascular mortality

Editorial

J H Chesebro et al. Cardiovasc Drugs Ther. 1989 Jun.

. 1989 Jun;3(3):353-4.

doi: 10.1007/BF01858107.

No abstract available

Similar articles

Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Barbarawi M, Kheiri B, Zayed Y, Gakhal I, Al-Abdouh A, Barbarawi O, Rashdan L, Rizk F, Bachuwa G, Alkotob ML. Barbarawi M, et al. High Blood Press Cardiovasc Prev. 2019 Aug;26(4):283-291. doi: 10.1007/s40292-019-00325-5. Epub 2019 Jul 6. High Blood Press Cardiovasc Prev. 2019. PMID: 31280451
Advancing the science of aspirin in primary prevention of vascular events.
[No authors listed] [No authors listed] Cardiovasc J Afr. 2007 Sep-Oct;18(5):347-8. Cardiovasc J Afr. 2007. PMID: 17985039 No abstract available.
[The role of aspirin in the primary prevention of cardiovascular disease].
Rodondi N, Cornuz J. Rodondi N, et al. Rev Med Suisse. 2006 Mar 8;2(56):646-51. Rev Med Suisse. 2006. PMID: 16597054 Review. French.
The aspirin controversy in primary prevention.
Raju NC, Eikelboom JW. Raju NC, et al. Curr Opin Cardiol. 2012 Sep;27(5):499-507. doi: 10.1097/HCO.0b013e328356ae95. Curr Opin Cardiol. 2012. PMID: 22874127 Review.
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA, Howard G. Bartolucci AA, et al. Am J Cardiol. 2006 Sep 15;98(6):746-50. doi: 10.1016/j.amjcard.2006.04.012. Epub 2006 Jul 26. Am J Cardiol. 2006. PMID: 16950176

Treatment of hypertension in the elderly--the end of the story?
Opie LH. Opie LH. Cardiovasc Drugs Ther. 1992 Dec;6(6):559-62; discussion 563-4. doi: 10.1007/BF00052553. Cardiovasc Drugs Ther. 1992. PMID: 1292573 Review.